DIFFLAM ORAL RINSE
- Name:
DIFFLAM ORAL RINSE
- Company:
Mylan IRE Healthcare Limited
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/06/20
(Click to Download)Click on this link to Download PDF directly
Mylan IRE Healthcare Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 19 June 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - excipient warnings
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 19 June 2020
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Updated on 6 December 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 5 December 2018
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Updated on 24 October 2016
Reasons for updating
- New SmPC for new product
Legal category: Supply through pharmacy only
Updated on 24 October 2016 SPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 4.8: Hypersensitivity has been added to immune system disorders. The ADR statement has been updated.
In section 4.9: Information has been added.
In section 10: The date of revision
Updated on 24 October 2016 PIL
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.8: Hypersensitivity has been added to immune system disorders. The ADR statement has been updated.
In section 4.9: Information has been added.
In section 10: The date of revision
Updated on 16 May 2016 PIL
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 6.5: Information that the graduated measuring cup has changed from 20ml to 30ml
In section 10: The date of revision has been changed.Updated on 16 May 2016 SPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 6.5: Information that the graduated measuring cup has changed from 20ml to 30ml
In section 10: The date of revision has been changed.Updated on 29 May 2014 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 4.4: these has been additional warnings added in relation to allergic reactions and to bronchospasm
In section 4.8: additional side effect of anaphylactic reaction has been added. Reporting information of adverse reaction to the IMB has been added
In section 5.1: Change in pharmacotherapeutic group. Additional information regarding the mode of action added. Pharmacodynamic effect information has been added. Clinical efficacy and safety text added.
In section 10: the date of revision has changed.
Updated on 29 May 2014 PIL
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.4: these has been additional warnings added in relation to allergic reactions and to bronchospasm
In section 4.8: additional side effect of anaphylactic reaction has been added. Reporting information of adverse reaction to the IMB has been added
In section 5.1: Change in pharmacotherapeutic group. Additional information regarding the mode of action added. Pharmacodynamic effect information has been added. Clinical efficacy and safety text added.
In section 10: the date of revision has changed.
Updated on 21 March 2011 SPC
Reasons for updating
- Change to section 5.2 - Pharmacokinetic properties
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 21 March 2011 PIL
Reasons for updating
- Change to section 5.2 - Pharmacokinetic properties
Free text change information supplied by the pharmaceutical company
Updated on 10 March 2011 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 10: the date of revision has changed to Feb 2011
Updated on 10 March 2011 PIL
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 10: the date of revision has changed to Feb 2011
Updated on 14 April 2009 PIL
Reasons for updating
- Correction of spelling/typing errors
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Free text change information supplied by the pharmaceutical company
Updated on 14 April 2009 SPC
Reasons for updating
- Correction of spelling/typing errors
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 12 September 2006 PIL
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Free text change information supplied by the pharmaceutical company
Updated on 12 September 2006 SPC
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 4 June 2003 SPC
Reasons for updating
- New SPC for new product
Legal category: Supply through pharmacy only
Updated on 4 June 2003 PIL
Reasons for updating
- New SPC for new product